Levalbuterol is a moderately selective short-acting beta-2-receptor agonist (SABA); it is the R-enantiomer of racemic albuterol and the therapeutically active enantiomer of the racemic compound. When administered in equimolar doses of R-albuterol (i.e., 2.5 mg of racemic albuterol or 1.25 mg of levalbuterol), levalbuterol produces bronchodilation and clinical activity similar to the parent drug. Levalbuterol is used for the treatment of bronchospasm due to reversible obstructive airway disease (e.g., asthma, asthma exacerbation) in adult and pediatric patients and for the treatment of chronic obstructive pulmonary disease (COPD) in adults. SABAs should not be used alone to manage asthma, but continue to be an option for reliever therapy in adult and pediatric patients with intermittent asthma and those with mild or moderate persistent asthma who are taking controller therapy such as inhaled corticosteroid (ICS) or ICS-long-acting beta-agonist (LABA) regimens. SABAs remain a key reliever therapy for infants and very young children (less than 4 years of age). However, guidelines now promote the use of "SMART" (single maintenance and reliever therapy) inhaler dosing strategies as preferred asthma management for selected adult and pediatric patients; such regimens usually combine an ICS with formoterol. SABAs also prevent exercise-induced bronchospasm (EIB), however, tolerance can develop with regular use and the incidence of EIB can usually be reduced with maintenance ICS therapy. According to guidelines, levalbuterol may be used for first-line therapy in patients with mild COPD (group A) and in combination with other treatments in those with more severe disease (groups B and E); inhaled SABAs are preferred for rescue therapy and for the management of acute COPD exacerbations, with or without an inhaled short-acting anticholinergic.
General Administration Information
For storage information, see the specific product information within the How Supplied section.
Route-Specific Administration
Inhalation Administration
Oral Inhalation Administration
Oral Inhalation (inhalation aerosol; metered-dose inhaler [MDI])
-Instruct the patient and/or caregiver on proper inhalation technique. Make sure the canister is firmly seated in the plastic mouthpiece actuator before each use. Shake the inhaler well. Prime the inhaler prior to the initial use by releasing 4 sprays into the air, away from the eyes and face. If not used for more than 3 days, re-prime the inhaler.
-For patients of any age unable to coordinate inhalation and actuation, a spacer or valved holding chamber (VHC) may be beneficial.
-The choice of using a mouthpiece versus a face mask with a spacer/VHC device must be made based on the skills and understanding of each individual patient. However, in general, children younger than 4 years require administration with a tight-fitting face mask and spacer/VHC device to achieve optimal delivery. If a face mask is used, allow 5 to 6 inhalations per actuation. Administer 1 puff at a time.
-If the patient is using other inhalers, instruct them to use levalbuterol first and wait 5 minutes, then use other inhalers as directed.
-After administration, instruct patient to rinse mouth with water to minimize dry mouth.
-The blue actuator (mouthpiece) supplied with levalbuterol (Xopenex HFA) should not be used with any other product canisters; conversely, actuators from other products should not be used with the levalbuterol (Xopenex HFA) canister.
-The dose indicator on the canister indicates the number of remaining inhalations. The dose indication display will move every tenth actuation. Towards the end of the usable inhalations, the color behind the number in the dose indicator window will change to red. Discard when the dose indicator display window shows zero.
-Clean the plastic mouthpiece of the inhaler at least once a week. After removing the medication canister wash the mouthpiece in warm running water. Shake excess water from the mouthpiece. Allow the actuator to air-dry completely. Blockage from medicine build up is more likely to occur if the actuator is not allowed to air-dry thoroughly. If build-up occurs, then washing the actuator will remove the blockage.
-To avoid the spread of infection, do not use the inhaler for more than one person.
Inhalation Solution for Nebulization
-For 3 mL inhalation solution vials: No dilution is necessary; the single-dose vials are ready-to-use.
-For 0.5 mL inhalation solution concentrate vials: Squeeze entire contents of vial into nebulizer reservoir; then, dilute solution to a final volume of 3 mL with sterile 0.9% NaCl Injection, and gently swirl nebulizer reservoir to mix.
-NOTE: For dosages less than 1.25 mg, the 3 mL inhalation solution vials must be used.
-Deliver solution by nebulization over 5 to 15 minutes.
-According to the manufacturer, the compatibility of levalbuterol inhalation solution with other drugs administered by nebulization has not been established; however, clinical guidelines state that levalbuterol nebulizer solution and budesonide suspension for nebulization are compatible in the same nebulizer.
-Safety and efficacy have been established when administered via PARI LC Jet or PARI LC Plus nebulizers and via PARI Master Dura-Neb 2000 or Dura-Neb 3000 compressors.
-The choice of using a mouthpiece versus a face mask must be made based on the skills and understanding of each individual patient.
-Using the 'blow by' technique (i.e., holding the face mask or open tube near the patient's nose and mouth) is not recommended.
-To avoid microbial contamination, aseptic technique should be used each time a multi-dose bottle is opened. Precautions should be taken to prevent contact of dropper tip with any surface, including nebulizer reservoir and ventilatory equipment. Each multi-dose bottle should be used for only 1 patient.
-Discard the vial if the solution is not colorless.
-Storage: Protect from light.-For 3 mL inhalation solution vials: Unit-dose vials should be stored in the protective foil pouch. If a vial is removed from the pouch and not used immediately, protect from light and use within 1 week. Once the protective foil pouch is opened use all contained vials within 2 weeks.
-For 0.5 mL inhalation solution concentrate vials: Use the contents of the vial immediately after the foil pouch is opened; do not store for future use.
As with other inhaled beta-2 agonists, levalbuterol can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs, immediately discontinue levalbuterol and initiate alternative therapy. In placebo controlled trials, asthma was reported. Reports in children age 6 to 11 getting nebulized drug were 9% with levalbuterol compared to 5.1% with placebo and 6.3-10% with racemic albuterol. Adults and adolescents 12 years and older reported asthma in 9% with metered dose inhaler, vs. 6% placebo. Wheezing occurred in less than 2% of adults who received nebulized levalbuterol and more frequently than in patients who received placebo.
Respiratory events reported in clinical trials include pharyngitis (3-10.4% levalbuterol, vs. 2-6.8% placebo and 0-13% albuterol), cough (1.4-4%, vs. 2.7% placebo and 2.7% albuterol), sinusitis (1.4-2.7%, vs. 2.7% placebo and 2.7% albuterol), bronchitis (3% vs. 0% placebo, only reported in 4-11 year olds with the inhaler), and turbinate edema (1.4-2.8%, vs. no reports with placebo or albuterol). Epistaxis and unspecified lung disorder (less than 2% with inhaler, age 12 and older) were reported more frequently with levalbuterol than in those who got placebo. Dysphonia was reported post-marketing.
Anaphylactoid reactions have been rarely reported with beta-agonist therapy. In levalbuterol clinical trials, rash (unspecified) (7.5%, vs. 0% placebo and 1.6% racemic albuterol), urticaria (3%, vs. no reports with placebo or albuterol), and unspecified allergic reaction were reported, which may be indicative of hypersensitivity. Similarly, angioedema and anaphylaxis were reported post-marketing. The rare cases of anaphylaxis, angioedema, bronchospasm, oropharyngeal edema, rash, and urticaria following racemic albuterol administration may indicate immediate hypersensitivity reactions; this would also apply to levalbuterol.
Sympathomimetic effects of beta-agonists are generally dose-related and, like other sympathomimetics, levalbuterol may increase heart rate and blood pressure. In clinical trials, sinus tachycardia was reported in 2.7% to 2.8% of adolescents and adults who received nebulized levalbuterol. Hypertension and chest pain (unspecified) occurred in less than 2% of adolescent and adult patients receiving levalbuterol oral inhalation or nebulization during clinical trials. If clinically significant symptoms occur at recommended doses (e.g., as measured by pulse rate, blood pressure) levalbuterol may need to be discontinued. Peripheral vasodilation can also occur from beta2-stimulation of vasculature; hypotension, and syncope have been reported in less than 2% of patients receiving levalbuterol nebulizations. In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T-wave, QT prolongation, and ST segment depression. The clinical significance of these findings is unknown. Cardiac effects may be related to sympathomimetic effects and/or beta-agonist-induced hypokalemia. Through stimulation of beta2-receptors, gluconeogenesis and intracellular movement of potassium occur and can lead to hyperglycemia and hypokalemia, although these effects usually occur with high dose nebulized inhalation administration. Arrhythmia exacerbation [e.g., atrial fibrillation, supraventricular tachycardia (SVT), extrasystoles], chest pain, and tachycardia have been reported with postmarketing experience.
Various types of infection, and symptoms of infection, were reported during clinical trials with levalbuterol, with both inhaler and nebulized solution formulations and in all populations studied (ranging from 4 years to adults). The most common reports included unspecified viral infection (up to 12.3%, vs. 5.1-9.3% placebo and 4.7-12.2% albuterol), flu syndrome (1.4-4%, vs. none with placebo and 2.7% with racemic albuterol), and ear pain (1.4-4%, vs. none with placebo and 2.7% with racemic albuterol) with no reports of otitis media in the levalbuterol group (vs. 1.7% with placebo and 3.3% with albuterol). In trials, unidentified cyst, acne vulgaris, herpes simplex, conjunctivitis, and ocular pruritus were reported in less than 2% of levalbuterol recipients and were reported more frequently than with placebo.
Dizziness (1.4% to 3%), nervousness (2.8% to 9.6%), tremor (6.8%), migraine (2.7%), asthenia (3%), and headache (7.6% to 11.9%) were reported during levalbuterol clinical trials at incidences greater than with placebo. Adverse reactions potentially related to levalbuterol that occurred in less than 2% of treated patients included hyperesthesia of the hand, insomnia, paresthesias, and anxiety. Postmarketing, similar to other sympathomimetic agents, adverse reactions such as nervousness, tremor, vertigo, central nervous system stimulation, sleeplessness and headache have been reported.
Dyspepsia (1.4-2.7% vs. 1.3% placebo and 1.4% albuterol), vomiting (11% vs. 6% placebo), abdominal pain (1.5% vs. 3.4% placebo and 3.1-6.7% albuterol), and diarrhea (1.5-6% vs. no reports with placebo and 1.6% albuterol) were reported during levalbuterol clinical trials. Adverse reactions potentially related to levalbuterol that occurred in less than 2% of those who received levalbuterol and more frequently than in patients who received placebo include xerostomia, dry throat, nausea, gastroenteritis, and constipation. Gastroesophageal reflux disease (GERD) was reported post-marketing.
Myalgia (1.5-2% vs. no reports with placebo and 3.3% albuterol) and pain (1.4-4% vs. 1.3-3.4% placebo and 2.7-6.7% albuterol), including leg muscle cramps (2.7% vs. 1.3% placebo and 1.4% albuterol) and back pain (no reports with levalbuterol of placebo, 2.7% albuterol) were reported during levalbuterol clinical trials.
Fever (3-9.1% in children age 6-11, 5.1% placebo and 1.6-6.7% albuterol), lymphadenopathy (less than 2% in adults and in 3% of children age 6-11, vs. no reports with placebo and 1.6% albuterol), and accidental injury (2.7-9% vs. 3.1-6% placebo and up to 5% albuterol) were reported during levalbuterol clinical trials. Adverse reactions potentially related to levalbuterol that occurred in less than 2% of those who received levalbuterol and more frequently than in patients who received placebo include sweating, chills, dysmenorrhea, vaginal candidiasis (moniliasis), and hematuria. Metabolic acidosis has been reported in post-marketing experience with levalbuterol inhalation solution and aerosol. A causal relationship has not been established. Diabetic ketoacidosis has been reported after administration of large doses of intravenous albuterol; the potential for this adverse event after the use of other albuterol dosage forms is unknown.
Do not exceed the recommended dose of levalbuterol; fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma. The exact cause of death is unknown; however, cardiac arrest following an unexpected development of a severe acute asthmatic crisis and subsequent hypoxia is suspected.
Levalbuterol is contraindicated in patients with a known levalbuterol hypersensitivity or albuterol hypersensitivity, or hypersensitivity to any component of the specific dosage formulation. Immediate hypersensitivity reactions may occur after administration of racemic albuterol, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema. Like other inhaled beta-agonists, levalbuterol inhalational solution can produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs, levalbuterol inhalational solution should be discontinued immediately and alternative therapy instituted. It should be recognized that paradoxical bronchospasm, when associated with inhaled formulations, frequently occurs with the first use of a new canister or vial.
Levalbuterol, like other sympathomimetic amines, should be used cautiously in patients with a history of seizure disorder, hyperthyroidism (thyrotoxicosis), pheochromocytoma, or unusual responsiveness to other sympathomimetic amines.
Monitor heart rate and blood pressure in patients receiving high doses of levalbuterol for acute asthma exacerbations; cardiovascular adverse effects are more likely to occur when aggressive doses are used. Levalbuterol, like other beta2-agonists and sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency (coronary artery disease), cardiac arrhythmias, and hypertension. Levalbuterol can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and cardiac arrhythmias, such as supraventricular tachycardia and extrasystoles. If such effects occur, levalbuterol may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiographic changes, such as flattening of the T wave, QT prolongation, and ST segment depression, although the clinical significance of these findings is unknown. Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. Beta-adrenergic agonist therapies like levalbuterol may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease in serum potassium is usually transient, not requiring supplementation.
A study of 5 patients with creatinine clearances ranging from 7 to 53 mL/minute showed that the renal clearance of levalbuterol was reduced by 67%, although the half-life of the drug was not affected. Since levalbuterol is substantially excreted by the kidney, the risk of toxic reactions may be greater in patients with renal impairment including renal failure. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
Levalbuterol should be used with caution in patients with diabetes mellitus. Large doses of intravenous racemic albuterol have been reported to aggravate preexisting diabetes mellitus and ketoacidosis.
Paradoxical bronchospasm can occur after treatment with levalbuterol and can be life-threatening. If this occurs, levalbuterol should be discontinued immediately and supportive care provided as necessary. Additionally, increased levalbuterol use may indicate asthma destabilization. Asthma may deteriorate acutely over a period of hours or chronically over several days or weeks. If deterioration of asthma occurs during therapy with levalbuterol, appropriate evaluation of the patient and the treatment strategy is warranted, giving special consideration to corticosteroid therapy. Levalbuterol has no anti-inflammatory activity and is not a substitute for inhaled or oral corticosteroid therapy. The use of beta-agonists alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents (e.g., corticosteroids) to the therapeutic regimen. Corticosteroids should not be stopped or reduced when levalbuterol therapy is instituted.
Safety and efficacy have not been established for neonates, infants, and children younger than 4 years of age for the aerosolized levalbuterol inhaler. Safety and efficacy have not been established for neonates, infants and children younger than 6 years of age for the nebulized levalbuterol product. Clinical trials of levalbuterol inhalation aerosol (n = 65; children younger than 4 years) and nebulized solution (n = 379; children younger than 6 years) failed to meet the primary efficacy endpoint and demonstrated an increased number of asthma-related adverse reactions with chronic treatment.
Pregnant women receiving levalbuterol should be closely monitored and medications adjusted as necessary to maintain optimal control. There are no adequate and well-controlled studies of levalbuterol during human pregnancy. Poorly controlled or moderately controlled asthma may present risks to pregnant women and to the fetus; there is an increased risk of preeclampsia in the mother and prematurity, low birth weight, and small for gestational age in the neonate. During postmarketing experience, various congenital anomalies, including cleft palate and limb defects, have been rarely reported in the infants of patients treated with racemic albuterol. Some of the mothers were taking multiple medications during their pregnancies. No consistent pattern of defects can be discerned, and a relationship between racemic albuterol and congenital anomalies has not been established. The National Asthma Education and Prevention Program (NAEPP) Asthma and Pregnancy Working Group include short-acting inhaled beta-2 agonists (SABAs) as first-line therapy for mild intermittent asthma during pregnancy, if treatment is required. Albuterol is preferred over other SABAs due to extensive safety-related information during pregnancy. However, there is no evidence of fetal injury with the use of other SABAs, and maintaining a previously established treatment regimen may be more beneficial to the patient. Due to the potential for beta-agonist interference with uterine contractility, the use of levalbuterol for acute relief of bronchospasm during labor and obstetric delivery should be restricted to those patients in whom the benefits clearly outweigh the risks. Levalbuterol is not approved for the management of pre-term labor; serious adverse events, including pulmonary edema, have been reported after treatment of premature labor with beta-2 agonists. A pregnancy registry is available to monitor pregnancy outcomes in women exposed to asthma medications, including levalbuterol. To enroll in MotherToBaby Pregnancy Studies' Asthma and Pregnancy Study, patients should call 1-877-311-8972 or visit www.mothertobaby.org/ongoing-study/asthma.
There are no available data on the presence of levalbuterol in human milk, the effects on the breast-fed infant, or the effects on milk production. According to the National Asthma Education and Prevention Program (NAEPP) working group for managing asthma during pregnancy, there is no contraindication for use of short-acting inhaled beta-2 agonists (SABAs) during breast-feeding. Plasma concentrations of levalbuterol after inhalation of therapeutic doses are very low in humans, but it is not known whether levalbuterol is excreted in human milk. Gastrointestinal absorption is likely low in the breastfed infant.
Beta-2 agonists, like levalbuterol, should be administered with extreme caution to patients being treated with MAOI therapy.
Clinical trials with levalbuterol nebulizer solution and inhalation aerosol did not include sufficient numbers of geriatric patients to determine if they respond differently than younger adults. general, patients 65 years of age and older should be started at lower doses (e.g., a dose of 0.63 mg per nebulizer dose). If clinically warranted due to insufficient bronchodilator response, the dose may be increased in elderly patients as tolerated, in conjunction with frequent clinical and laboratory monitoring, to the maximum recommended daily adult dose. Since levalbuterol is substantially excreted by the kidney, the risk of toxic reactions may be greater in patients with renal impairment, including geriatric patients with an age-related decline in renal function. It may be useful to monitor renal function. Geriatric patients may be more sensitive to the side effects of beta-agonists, including tremor, tachycardia, and QT prolongation. The federal Omnibus Budget Reconciliation Act (OBRA) regulates medication use in residents of long-term care facilities (LTCFs). The OBRA guidelines caution that inhaled beta-agonists, such as levalbuterol, can cause restlessness, increased heart rate, and anxiety.
For the treatment of asthma exacerbation:
Respiratory (Inhalation) dosage (inhalation solution):
Adults: 1.25 to 2.5 mg inhaled by nebulizer every 20 minutes for the first hour, then 1.25 to 5 mg inhaled by nebulizer every 1 to 4 hours as needed.
Adolescents: 1.25 to 2.5 mg inhaled by nebulizer every 20 minutes for the first hour, then 1.25 to 5 mg inhaled by nebulizer every 1 to 4 hours as needed.
Children 6 to 12 years: 1.25 mg inhaled by nebulizer every 20 minutes for the first hour, then 0.075 to 0.15 mg/kg/dose (Max: 5 mg/dose) inhaled by nebulizer every 1 to 4 hours as needed.
Infants* and Children* 1 to 5 years: 1.25 mg inhaled by nebulizer every 20 minutes for the first hour, then 0.075 to 0.15 mg/kg/dose (Max: 5 mg/dose) inhaled by nebulizer every 1 to 4 hours as needed.
Respiratory (Inhalation) dosage (inhalation aerosol)*:
Adults: 180 to 360 mcg (4 to 8 actuations of 45 mcg/actuation) every 20 minutes for up to 4 hours, then every 1 to 4 hours as needed.
Adolescents: 180 to 360 mcg (4 to 8 actuations of 45 mcg/actuation) every 20 minutes for the first hour, then every 1 to 4 hours as needed.
Infants and Children: 180 to 360 mcg (4 to 8 actuations of 45 mcg/actuation) every 20 minutes for the first hour, then every 1 to 4 hours as needed. Delivery should occur with a spacer, with a mask for children younger than 4 years.
For the treatment of transient increase in bronchospasm (e.g., episodic wheezing) as asthma reliever therapy:
Respiratory (Inhalation) dosage (inhalation aerosol; e.g., Xopenex HFA):
Adults: 90 mcg (2 actuations of 45 mcg/actuation) inhaled by mouth every 4 to 6 hours as needed; 45 mcg (1 actuation) every 4 hours may be sufficient. Max: 540 mcg/day (12 actuations/day).
Children and Adolescents 4 to 17 years: 90 mcg (2 actuations of 45 mcg/actuation) inhaled by mouth every 4 to 6 hours as needed; 45 mcg (1 actuation) every 4 hours may be sufficient. Max: 540 mcg/day (12 actuations/day).
Respiratory (Inhalation) dosage (inhalation solution):
Adults: 0.63 or 1.25 mg inhaled by nebulizer 3 times daily, every 6 to 8 hours, as needed. In the geriatric adult, the lower dose of 0.63 mg is recommended initially. Max: 3.75 mg/day.
Children and Adolescents 12 to 17 years: 0.63 or 1.25 mg inhaled by nebulizer 3 times daily, every 6 to 8 hours, as needed. Max: 3.75 mg/day.
Children 6 to 11 years: 0.31 or 0.63 mg inhaled by nebulizer 3 times daily as needed. Max: 1.89 mg/day.
For exercise-induced bronchospasm prophylaxis*:
Respiratory (Inhalation) dosage (inhalation aerosol):
Adults: 90 mcg (2 actuations of 45 mcg/actuation) inhaled by mouth 5 to 20 minutes before exercise. A controller agent (e.g., daily inhaled corticosteroid) is recommended to be used along with as-needed and pre-exercise short-acting beta-agonists like levalbuterol.
Children and Adolescents 4 to 17 years: 90 mcg (2 actuations of 45 mcg/actuation) inhaled by mouth 5 to 20 minutes before exercise. A controller agent (e.g., daily inhaled corticosteroid) is recommended to be used along with as-needed and pre-exercise SABAs like levalbuterol.
For the treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) (e.g., chronic bronchitis or emphysema):
-for the treatment of COPD exacerbation:
Respiratory (Inhalation) dosage (inhalation aerosol; e.g., Xopenex HFA):
Adults: 45 or 90 mcg (1 or 2 actuations of 45 mcg/actuation) inhaled by mouth every 1 hour for 2 to 3 doses, then 45 or 90 mcg (1 or 2 actuations of 45 mcg/actuation) inhaled by mouth every 2 to 4 hours as needed. The FDA-approved dosage is 90 mcg (2 actuations of 45 mcg/actuation) inhaled by mouth every 4 to 6 hours as needed. In some persons, 45 mcg (1 actuation of 45 mcg/actuation) inhaled by mouth every 4 hours may be sufficient. Guidelines recommend a short-acting inhaled beta-2 agonist (SABA), with or without a short-acting anticholinergic, as the initial bronchodilators for acute treatment of a COPD exacerbation. Use of a metered-dose inhaler is recommended rather than continuous nebulization to deliver the SABA. No significant differences in FEV1 have been demonstrated between metered-dose inhalers (with or without a spacer) or nebulizers to deliver the SABA; nebulizers may be more convenient for persons who are more acutely ill.
Respiratory (Inhalation) dosage (inhalation solution):
Adults: Optimal dosing is not established. 0.63 or 1.25 mg inhaled by nebulizer 3 times daily, every 6 to 8 hours, as needed. In the geriatric adult, the lower dose of 0.63 mg is recommended initially. Max: 3.75 mg/day. Guidelines recommend a short-acting inhaled beta-2 agonist (SABA), with or without a short-acting anticholinergic, as the initial bronchodilators for acute treatment of a COPD exacerbation. Use of a metered-dose inhaler is recommended rather than continuous nebulization to deliver the SABA. No significant differences in FEV1 have been demonstrated between metered-dose inhalers (with or without a spacer) or nebulizers to deliver the SABA; nebulizers may be more convenient for persons who are more acutely ill.
-for the treatment of stable COPD:
Respiratory (Inhalation) dosage (inhalation aerosol; e.g., Xopenex HFA):
Adults: 90 mcg (2 actuations of 45 mcg/actuation) inhaled by mouth every 4 to 6 hours as needed. In some persons, 45 mcg (1 actuation of 45 mcg/actuation) inhaled by mouth every 4 hours may be sufficient. Max: 540 mcg/day (12 actuations/day). Guidelines recommend a bronchodilator in persons with 0 or 1 moderate exacerbations per year (not leading to hospital admission) and modified Medical Research Council (mMRC) dyspnea questionnaire score of 0 to 1 and COPD Assessment Test (CAT) score of less than 10. Long-acting bronchodilators are preferred over short-acting bronchodilators except for persons with occasional dyspnea and for immediate relief of symptoms in persons already receiving long-acting bronchodilators for maintenance therapy. Inhaled bronchodilators are commonly given on a regular basis to prevent or reduce symptoms. Regular and as-needed use of a short-acting beta-2 agonist (SABA) improves FEV1 and symptoms.
Respiratory (Inhalation) dosage (inhalation solution):
Adults: 0.63 or 1.25 mg inhaled by nebulizer 3 times daily, every 6 to 8 hours, as needed. In the geriatric adult, the lower dose of 0.63 mg is recommended initially. Max: 3.75 mg/day. Guidelines recommend a bronchodilator in persons with 0 or 1 moderate exacerbations per year (not leading to hospital admission) and modified Medical Research Council (mMRC) dyspnea questionnaire score of 0 to 1 and COPD Assessment Test (CAT) score of less than 10. Long-acting bronchodilators are preferred over short-acting bronchodilators except for persons with occasional dyspnea and for immediate relief of symptoms in persons already receiving long-acting bronchodilators for maintenance therapy. Inhaled bronchodilators are commonly given on a regular basis to prevent or reduce symptoms. Regular and as-needed use of a short-acting beta-2 agonist (SABA) improves FEV1 and symptoms.
For the adjunctive emergency acute treatment of hyperkalemia* until hemodialysis is available:
Nebulizer Inhalation dosage (solution for nebulization; various concentrations):
Adults*: Single doses of levalbuterol 2.5 mg have been administered in one trial of healthy adults and are reportedly as effective as albuterol 10 mg nebulized. K+ concentrations usually fall within 30 minutes of treatment. Levalbuterol reportedly results in fewer reported side effects than albuterol; however, it is more costly. Beta-agonists can be effective treatments for hyperkalemia via beta-adrenergic induction of potassium (K+) uptake. However, they are a temporary adjunctive measure.
For adjunctive treatment of neonatal respiratory illness, such as those with suspected airway reactivity*, bronchopulmonary dysplasia*, or chronic lung disease (CLD)*:
Nebulized Inhalation dosage (solution for nebulization):
Premature neonates: 0.31 mg via nebulizer every 8 hours was used in a retrospective analysis comparing levalbuterol (n = 31, mean corrected gestational age 31.4 weeks, mean birth weight 1.1 kg) to albuterol (1.25 mg every 8 hours, n = 16, mean corrected gestational age 29.9 weeks, mean birth weight 817 g). Investigators found no difference between albuterol and levalbuterol groups in relation to heart rate, oxygen supplementation, oxygen saturations, respiratory rate, hypokalemia, or hyperglycemia. A significant decrease in mean arterial blood pressure was observed in patients given albuterol versus levalbuterol; however, dosing differed between the 2 groups with patients administered albuterol receiving a dose that is twice the equivalent dose of levalbuterol.
Maximum Dosage Limits:
-Adults
2 puffs (MDI) every 4 hours as needed for treatment/prevention of bronchospasm; higher doses may be required acutely during severe exacerbations. For nebulized solution, 1.25 mg/dose given 3 times/day for treatment/prevention of bronchospasm.
-Geriatric
2 puffs (MDI) every 4 hours as needed for treatment/prevention of bronchospasm; higher doses may be required acutely during severe exacerbations. For nebulized solution, 1.25 mg/dose given 3 times/day for treatment/prevention of bronchospasm.
-Adolescents
2 puffs (MDI) every 4 hours as needed for treatment/prevention of bronchospasm; higher doses may be required acutely during severe asthma exacerbations. For nebulized solution, 1.25 mg/dose given 3 times/day for treatment/prevention of bronchospasm; doses up to 5 mg/dose have been used off-label for acute exacerbations.
-Children
12 years: 2 puffs (MDI) every 4 hours as needed for treatment/prevention of bronchospasm; higher doses may be required acutely during severe asthma exacerbations. For nebulized solution, 1.25 mg/dose given 3 times/day for treatment/prevention of bronchospasm; doses up to 5 mg/dose have been used off-label for acute exacerbations.
6 to 11 years: 2 puffs (MDI) every 4 hours as needed for treatment/prevention of bronchospasm; higher doses may be required acutely during severe asthma exacerbations. For nebulized solution, 0.63 mg/dose given 3 times/day for treatment/prevention of bronchospasm; doses up to 0.15 mg/kg/dose (Max: 5 mg/dose) have been used off-label for acute exacerbations.
4 to 5 years: 2 puffs (MDI) every 4 hours as needed for treatment/prevention of bronchospasm; higher doses may be required acutely during severe asthma exacerbations. Safety and efficacy of the nebulized oral solution has not been established; however, doses up to 0.15 mg/kg/dose (Max: 5 mg/dose) have been used off-label for acute exacerbations.
1 to 3 years: Safety and efficacy have not been established.
-Infants
Safety and efficacy have not been established.
-Neonates
Safety and efficacy have not been established; however, 0.31 mg via nebulizer every 8 hours has been used off-label for bronchodilation.
Patients with Hepatic Impairment Dosing
No dosage adjustments are needed.
Patients with Renal Impairment Dosing
No specific dosage adjustments are recommended; caution may be warranted during the administration of high doses in patients with renal impairment, as renal clearance is reduced.
*non-FDA-approved indication
Acebutolol: (Moderate) Beta-blockers will block the pulmonary effects of inhaled beta-agonists, and in some cases may exacerbate bronchospasm in patients with reactive airways. Beta-agonists can sometimes increase heart rate or have other cardiovascular effects, particularly when used in high doses or if hypokalemia is present. Use of a beta-1-selective (cardioselective) beta blocker is recommended whenever possible when this combination of drugs must be used together. Monitor the patient's lung and cardiovascular status closely. Beta-agonists and beta-blockers are pharmacologic opposites and will counteract each other to some extent when given concomitantly, especially when non-cardioselective beta blockers are used.
Acetaminophen; Aspirin, ASA; Caffeine: (Moderate) Caffeine may enhance the cardiac inotropic effects of beta-agonists.
Acetaminophen; Aspirin, ASA; Caffeine: (Moderate) Caffeine may enhance the cardiac inotropic effects of beta-agonists.
Acetaminophen; Caffeine: (Moderate) Caffeine may enhance the cardiac inotropic effects of beta-agonists.
Acetaminophen; Caffeine; Dihydrocodeine: (Moderate) Caffeine may enhance the cardiac inotropic effects of beta-agonists.
Acetaminophen; Caffeine; Pyrilamine: (Moderate) Caffeine may enhance the cardiac inotropic effects of beta-agonists.
Acetaminophen; Chlorpheniramine; Dextromethorphan; Phenylephrine: (Moderate) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Acetaminophen; Chlorpheniramine; Dextromethorphan; Pseudoephedrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and pseudoephedrine use. Concomitant use may potentiate sympathetic effects.
Acetaminophen; Chlorpheniramine; Phenylephrine : (Moderate) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Acetaminophen; Dextromethorphan; Guaifenesin; Phenylephrine: (Moderate) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Acetaminophen; Dextromethorphan; Guaifenesin; Pseudoephedrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and pseudoephedrine use. Concomitant use may potentiate sympathetic effects.
Acetaminophen; Dextromethorphan; Phenylephrine: (Moderate) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Acetaminophen; Dextromethorphan; Pseudoephedrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and pseudoephedrine use. Concomitant use may potentiate sympathetic effects.
Acetaminophen; Guaifenesin; Phenylephrine: (Moderate) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Acetaminophen; Phenylephrine: (Moderate) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Acetaminophen; Pseudoephedrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and pseudoephedrine use. Concomitant use may potentiate sympathetic effects.
Acetazolamide: (Moderate) Albuterol may cause additive hypokalemia when coadministered with carbonic anhydrase inhibitors. These combinations can lead to symptomatic hypokalemia and associated ECG changes in some susceptible individuals. Monitoring of potassium levels would be advisable.
Acrivastine; Pseudoephedrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and pseudoephedrine use. Concomitant use may potentiate sympathetic effects.
Aliskiren; Hydrochlorothiazide, HCTZ: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Amiloride; Hydrochlorothiazide, HCTZ: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Amlodipine; Valsartan; Hydrochlorothiazide, HCTZ: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Amphetamine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and amphetamine; dextroamphetamine use. Concomitant use may potentiate sympathetic effects.
Amphetamine; Dextroamphetamine Salts: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and amphetamine; dextroamphetamine use. Concomitant use may potentiate sympathetic effects.
Amphetamine; Dextroamphetamine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and amphetamine; dextroamphetamine use. Concomitant use may potentiate sympathetic effects.
Articaine; Epinephrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and epinephrine use. Concomitant use may potentiate sympathetic effects.
Aspirin, ASA; Butalbital; Caffeine: (Moderate) Caffeine may enhance the cardiac inotropic effects of beta-agonists.
Aspirin, ASA; Caffeine: (Moderate) Caffeine may enhance the cardiac inotropic effects of beta-agonists.
Aspirin, ASA; Caffeine; Orphenadrine: (Moderate) Caffeine may enhance the cardiac inotropic effects of beta-agonists.
Atenolol: (Moderate) Beta-blockers will block the pulmonary effects of inhaled beta-agonists, and in some cases may exacerbate bronchospasm in patients with reactive airways. Beta-agonists can sometimes increase heart rate or have other cardiovascular effects, particularly when used in high doses or if hypokalemia is present. Use of a beta-1-selective (cardioselective) beta blocker is recommended whenever possible when this combination of drugs must be used together. Monitor the patient's lung and cardiovascular status closely. Beta-agonists and beta-blockers are pharmacologic opposites and will counteract each other to some extent when given concomitantly, especially when non-cardioselective beta blockers are used.
Atenolol; Chlorthalidone: (Moderate) Beta-blockers will block the pulmonary effects of inhaled beta-agonists, and in some cases may exacerbate bronchospasm in patients with reactive airways. Beta-agonists can sometimes increase heart rate or have other cardiovascular effects, particularly when used in high doses or if hypokalemia is present. Use of a beta-1-selective (cardioselective) beta blocker is recommended whenever possible when this combination of drugs must be used together. Monitor the patient's lung and cardiovascular status closely. Beta-agonists and beta-blockers are pharmacologic opposites and will counteract each other to some extent when given concomitantly, especially when non-cardioselective beta blockers are used. (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Azilsartan; Chlorthalidone: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Benazepril; Hydrochlorothiazide, HCTZ: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Benzphetamine: (Moderate) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Beta-adrenergic blockers: (Moderate) Beta-blockers will block the pulmonary effects of inhaled beta-agonists, and in some cases may exacerbate bronchospasm in patients with reactive airways. Beta-agonists can sometimes increase heart rate or have other cardiovascular effects, particularly when used in high doses or if hypokalemia is present. Use of a beta-1-selective (cardioselective) beta blocker is recommended whenever possible when this combination of drugs must be used together. Monitor the patient's lung and cardiovascular status closely. Beta-agonists and beta-blockers are pharmacologic opposites and will counteract each other to some extent when given concomitantly, especially when non-cardioselective beta blockers are used.
Betaxolol: (Moderate) Beta-blockers will block the pulmonary effects of inhaled beta-agonists, and in some cases may exacerbate bronchospasm in patients with reactive airways. Beta-agonists can sometimes increase heart rate or have other cardiovascular effects, particularly when used in high doses or if hypokalemia is present. Use of a beta-1-selective (cardioselective) beta blocker is recommended whenever possible when this combination of drugs must be used together. Monitor the patient's lung and cardiovascular status closely. Beta-agonists and beta-blockers are pharmacologic opposites and will counteract each other to some extent when given concomitantly, especially when non-cardioselective beta blockers are used.
Bisoprolol: (Moderate) Beta-blockers will block the pulmonary effects of inhaled beta-agonists, and in some cases may exacerbate bronchospasm in patients with reactive airways. Beta-agonists can sometimes increase heart rate or have other cardiovascular effects, particularly when used in high doses or if hypokalemia is present. Use of a beta-1-selective (cardioselective) beta blocker is recommended whenever possible when this combination of drugs must be used together. Monitor the patient's lung and cardiovascular status closely. Beta-agonists and beta-blockers are pharmacologic opposites and will counteract each other to some extent when given concomitantly, especially when non-cardioselective beta blockers are used.
Bisoprolol; Hydrochlorothiazide, HCTZ: (Moderate) Beta-blockers will block the pulmonary effects of inhaled beta-agonists, and in some cases may exacerbate bronchospasm in patients with reactive airways. Beta-agonists can sometimes increase heart rate or have other cardiovascular effects, particularly when used in high doses or if hypokalemia is present. Use of a beta-1-selective (cardioselective) beta blocker is recommended whenever possible when this combination of drugs must be used together. Monitor the patient's lung and cardiovascular status closely. Beta-agonists and beta-blockers are pharmacologic opposites and will counteract each other to some extent when given concomitantly, especially when non-cardioselective beta blockers are used. (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Brimonidine; Timolol: (Moderate) Beta-blockers will block the pulmonary effects of inhaled beta-agonists, and in some cases may exacerbate bronchospasm in patients with reactive airways. Beta-agonists can sometimes increase heart rate or have other cardiovascular effects, particularly when used in high doses or if hypokalemia is present. Use of a beta-1-selective (cardioselective) beta blocker is recommended whenever possible when this combination of drugs must be used together. Monitor the patient's lung and cardiovascular status closely. Beta-agonists and beta-blockers are pharmacologic opposites and will counteract each other to some extent when given concomitantly, especially when non-cardioselective beta blockers are used.
Brompheniramine; Dextromethorphan; Phenylephrine: (Moderate) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Brompheniramine; Phenylephrine: (Moderate) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Brompheniramine; Pseudoephedrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and pseudoephedrine use. Concomitant use may potentiate sympathetic effects.
Brompheniramine; Pseudoephedrine; Dextromethorphan: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and pseudoephedrine use. Concomitant use may potentiate sympathetic effects.
Bumetanide: (Moderate) Use beta-agonists and loop diuretics with caution due to risk for ECG changes and/or hypokalemia. The ECG changes and/or hypokalemia that may result from administration of loop diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.
Bupivacaine; Epinephrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and epinephrine use. Concomitant use may potentiate sympathetic effects.
Butalbital; Acetaminophen; Caffeine: (Moderate) Caffeine may enhance the cardiac inotropic effects of beta-agonists.
Butalbital; Acetaminophen; Caffeine; Codeine: (Moderate) Caffeine may enhance the cardiac inotropic effects of beta-agonists.
Butalbital; Aspirin; Caffeine; Codeine: (Moderate) Caffeine may enhance the cardiac inotropic effects of beta-agonists.
Caffeine: (Moderate) Caffeine may enhance the cardiac inotropic effects of beta-agonists.
Caffeine; Sodium Benzoate: (Moderate) Caffeine may enhance the cardiac inotropic effects of beta-agonists.
Candesartan; Hydrochlorothiazide, HCTZ: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Captopril; Hydrochlorothiazide, HCTZ: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Carbonic anhydrase inhibitors: (Moderate) Albuterol may cause additive hypokalemia when coadministered with carbonic anhydrase inhibitors. These combinations can lead to symptomatic hypokalemia and associated ECG changes in some susceptible individuals. Monitoring of potassium levels would be advisable.
Carteolol: (Moderate) Beta-blockers will block the pulmonary effects of inhaled beta-agonists, and in some cases may exacerbate bronchospasm in patients with reactive airways. Beta-agonists can sometimes increase heart rate or have other cardiovascular effects, particularly when used in high doses or if hypokalemia is present. Use of a beta-1-selective (cardioselective) beta blocker is recommended whenever possible when this combination of drugs must be used together. Monitor the patient's lung and cardiovascular status closely. Beta-agonists and beta-blockers are pharmacologic opposites and will counteract each other to some extent when given concomitantly, especially when non-cardioselective beta blockers are used.
Carvedilol: (Moderate) Beta-blockers will block the pulmonary effects of inhaled beta-agonists, and in some cases may exacerbate bronchospasm in patients with reactive airways. Beta-agonists can sometimes increase heart rate or have other cardiovascular effects, particularly when used in high doses or if hypokalemia is present. Use of a beta-1-selective (cardioselective) beta blocker is recommended whenever possible when this combination of drugs must be used together. Monitor the patient's lung and cardiovascular status closely. Beta-agonists and beta-blockers are pharmacologic opposites and will counteract each other to some extent when given concomitantly, especially when non-cardioselective beta blockers are used.
Cetirizine; Pseudoephedrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and pseudoephedrine use. Concomitant use may potentiate sympathetic effects.
Chlophedianol; Dexchlorpheniramine; Pseudoephedrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and pseudoephedrine use. Concomitant use may potentiate sympathetic effects.
Chlorothiazide: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Chlorpheniramine; Dextromethorphan; Phenylephrine: (Moderate) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Chlorpheniramine; Dextromethorphan; Pseudoephedrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and pseudoephedrine use. Concomitant use may potentiate sympathetic effects.
Chlorpheniramine; Ibuprofen; Pseudoephedrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and pseudoephedrine use. Concomitant use may potentiate sympathetic effects.
Chlorpheniramine; Phenylephrine: (Moderate) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Chlorpheniramine; Pseudoephedrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and pseudoephedrine use. Concomitant use may potentiate sympathetic effects.
Chlorthalidone: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Cisapride: (Contraindicated) QT prolongation and ventricular arrhythmias, including torsade de pointes (TdP) and death, have been reported with cisapride. Because of the potential for TdP, use of other drugs that might increase the QT interval is contraindicated with cisapride. Beta-agonists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses and/or when associated with hypokalemia.
Cocaine: (Moderate) Additive effects and increased toxicity might be observed when using cocaine with beta-agonists, which are sympathomimetic agents. The combined use of these agents may have the potential for additive adrenergic stimulation and side effects, such as nervousness, insomnia, palpitations, or adverse cardiovascular effects.
Codeine; Guaifenesin; Pseudoephedrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and pseudoephedrine use. Concomitant use may potentiate sympathetic effects.
Codeine; Phenylephrine; Promethazine: (Moderate) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Desloratadine; Pseudoephedrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and pseudoephedrine use. Concomitant use may potentiate sympathetic effects.
Dexbrompheniramine; Pseudoephedrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and pseudoephedrine use. Concomitant use may potentiate sympathetic effects.
Dexchlorpheniramine; Dextromethorphan; Pseudoephedrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and pseudoephedrine use. Concomitant use may potentiate sympathetic effects.
Dextroamphetamine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and amphetamine; dextroamphetamine use. Concomitant use may potentiate sympathetic effects.
Dextromethorphan; Diphenhydramine; Phenylephrine: (Moderate) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Dextromethorphan; Guaifenesin; Phenylephrine: (Moderate) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Dextromethorphan; Guaifenesin; Pseudoephedrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and pseudoephedrine use. Concomitant use may potentiate sympathetic effects.
Dichlorphenamide: (Moderate) Use dichlorphenamide and albuterol together with caution. Metabolic acidosis has been reported with dichlorphenamide and albuterol aerosol and inhalation solution. Concurrent use may increase the severity of metabolic acidosis. Measure sodium bicarbonate concentrations at baseline and periodically during dichlorphenamide treatment. If metabolic acidosis occurs or persists, consider reducing the dose or discontinuing dichlorphenamide therapy.
Diethylpropion: (Major) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Digoxin: (Moderate) Mean decreases of 16% and 22% in serum digoxin levels were demonstrated after single-dose intravenous and oral administration of racemic albuterol, respectively, to normal volunteers who had received digoxin for 10 days. The clinical significance of these findings for patients with obstructive airway disease who are receiving albuterol or levalbuterol and digoxin on a chronic basis is unclear. The manufacturer of digoxin recommends measuring serum digoxin concentrations prior to initiation of albuterol or levalbuterol. Continue monitoring during concomitant treatment and increase the digoxin dose by 20 to 40% as necessary.
Diphenhydramine; Phenylephrine: (Moderate) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Dobutamine: (Major) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Dopamine: (Major) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Dorzolamide; Timolol: (Moderate) Beta-blockers will block the pulmonary effects of inhaled beta-agonists, and in some cases may exacerbate bronchospasm in patients with reactive airways. Beta-agonists can sometimes increase heart rate or have other cardiovascular effects, particularly when used in high doses or if hypokalemia is present. Use of a beta-1-selective (cardioselective) beta blocker is recommended whenever possible when this combination of drugs must be used together. Monitor the patient's lung and cardiovascular status closely. Beta-agonists and beta-blockers are pharmacologic opposites and will counteract each other to some extent when given concomitantly, especially when non-cardioselective beta blockers are used.
Doxapram: (Major) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Enalapril; Hydrochlorothiazide, HCTZ: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Ephedrine: (Major) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Ephedrine; Guaifenesin: (Major) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Epinephrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and epinephrine use. Concomitant use may potentiate sympathetic effects.
Eprosartan; Hydrochlorothiazide, HCTZ: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Ergotamine; Caffeine: (Moderate) Caffeine may enhance the cardiac inotropic effects of beta-agonists.
Esmolol: (Moderate) Beta-blockers will block the pulmonary effects of inhaled beta-agonists, and in some cases may exacerbate bronchospasm in patients with reactive airways. Beta-agonists can sometimes increase heart rate or have other cardiovascular effects, particularly when used in high doses or if hypokalemia is present. Use of a beta-1-selective (cardioselective) beta blocker is recommended whenever possible when this combination of drugs must be used together. Monitor the patient's lung and cardiovascular status closely. Beta-agonists and beta-blockers are pharmacologic opposites and will counteract each other to some extent when given concomitantly, especially when non-cardioselective beta blockers are used.
Ethacrynic Acid: (Moderate) Use beta-agonists and loop diuretics with caution due to risk for ECG changes and/or hypokalemia. The ECG changes and/or hypokalemia that may result from administration of loop diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.
Fexofenadine; Pseudoephedrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and pseudoephedrine use. Concomitant use may potentiate sympathetic effects.
Fosinopril; Hydrochlorothiazide, HCTZ: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Furosemide: (Moderate) Use beta-agonists and loop diuretics with caution due to risk for ECG changes and/or hypokalemia. The ECG changes and/or hypokalemia that may result from administration of loop diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.
Green Tea: (Moderate) Some green tea products contain caffeine, which is a CNS-stimulant. Additive effects are expected if used in combination with other CNS stimulants including the beta-agonists.
Guaifenesin; Phenylephrine: (Moderate) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Guaifenesin; Pseudoephedrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and pseudoephedrine use. Concomitant use may potentiate sympathetic effects.
Hydrochlorothiazide, HCTZ: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Hydrochlorothiazide, HCTZ; Moexipril: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Ibuprofen; Pseudoephedrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and pseudoephedrine use. Concomitant use may potentiate sympathetic effects.
Irbesartan; Hydrochlorothiazide, HCTZ: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Isocarboxazid: (Moderate) Use beta-agonists with caution in patients receiving concomitant monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping treatment with MAOIs because the action of beta-agonists on the cardiovascular system may be potentiated.
Isoproterenol: (Major) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Labetalol: (Moderate) Beta-blockers will block the pulmonary effects of inhaled beta-agonists, and in some cases may exacerbate bronchospasm in patients with reactive airways. Beta-agonists can sometimes increase heart rate or have other cardiovascular effects, particularly when used in high doses or if hypokalemia is present. Use of a beta-1-selective (cardioselective) beta blocker is recommended whenever possible when this combination of drugs must be used together. Monitor the patient's lung and cardiovascular status closely. Beta-agonists and beta-blockers are pharmacologic opposites and will counteract each other to some extent when given concomitantly, especially when non-cardioselective beta blockers are used.
Levobunolol: (Moderate) Beta-blockers will block the pulmonary effects of inhaled beta-agonists, and in some cases may exacerbate bronchospasm in patients with reactive airways. Beta-agonists can sometimes increase heart rate or have other cardiovascular effects, particularly when used in high doses or if hypokalemia is present. Use of a beta-1-selective (cardioselective) beta blocker is recommended whenever possible when this combination of drugs must be used together. Monitor the patient's lung and cardiovascular status closely. Beta-agonists and beta-blockers are pharmacologic opposites and will counteract each other to some extent when given concomitantly, especially when non-cardioselective beta blockers are used.
Levothyroxine: (Moderate) Monitor blood pressure and heart rate during concomitant beta-agonist and thyroid hormone use. Concurrent use may increase the effects of sympathomimetics or thyroid hormone. Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease.
Levothyroxine; Liothyronine (Porcine): (Moderate) Monitor blood pressure and heart rate during concomitant beta-agonist and thyroid hormone use. Concurrent use may increase the effects of sympathomimetics or thyroid hormone. Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease.
Levothyroxine; Liothyronine (Synthetic): (Moderate) Monitor blood pressure and heart rate during concomitant beta-agonist and thyroid hormone use. Concurrent use may increase the effects of sympathomimetics or thyroid hormone. Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease.
Lidocaine; Epinephrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and epinephrine use. Concomitant use may potentiate sympathetic effects.
Linezolid: (Moderate) Linezolid may enhance the hypertensive effect of beta-agonists. Closely monitor for increased blood pressure during coadministration. Linezolid is an antibiotic that is also a weak, reversible nonselective inhibitor of monoamine oxidase (MAO). Therefore, linezolid has the potential for interaction with adrenergic agents, such as the beta-agonists.
Liothyronine: (Moderate) Monitor blood pressure and heart rate during concomitant beta-agonist and thyroid hormone use. Concurrent use may increase the effects of sympathomimetics or thyroid hormone. Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease.
Lisdexamfetamine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and lisdexamfetamine use. Concomitant use may potentiate sympathetic effects.
Lisinopril; Hydrochlorothiazide, HCTZ: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Loop diuretics: (Moderate) Use beta-agonists and loop diuretics with caution due to risk for ECG changes and/or hypokalemia. The ECG changes and/or hypokalemia that may result from administration of loop diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.
Loratadine; Pseudoephedrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and pseudoephedrine use. Concomitant use may potentiate sympathetic effects.
Losartan; Hydrochlorothiazide, HCTZ: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Methacholine: (Major) Discontinue use of short-acting beta-agonists 6 hours before a methacholine challenge test. Beta-agonists inhibit the airway response to methacholine.
Methamphetamine: (Moderate) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Methazolamide: (Moderate) Albuterol may cause additive hypokalemia when coadministered with carbonic anhydrase inhibitors. These combinations can lead to symptomatic hypokalemia and associated ECG changes in some susceptible individuals. Monitoring of potassium levels would be advisable.
Metolazone: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Metoprolol: (Moderate) Beta-blockers will block the pulmonary effects of inhaled beta-agonists, and in some cases may exacerbate bronchospasm in patients with reactive airways. Beta-agonists can sometimes increase heart rate or have other cardiovascular effects, particularly when used in high doses or if hypokalemia is present. Use of a beta-1-selective (cardioselective) beta blocker is recommended whenever possible when this combination of drugs must be used together. Monitor the patient's lung and cardiovascular status closely. Beta-agonists and beta-blockers are pharmacologic opposites and will counteract each other to some extent when given concomitantly, especially when non-cardioselective beta blockers are used.
Metoprolol; Hydrochlorothiazide, HCTZ: (Moderate) Beta-blockers will block the pulmonary effects of inhaled beta-agonists, and in some cases may exacerbate bronchospasm in patients with reactive airways. Beta-agonists can sometimes increase heart rate or have other cardiovascular effects, particularly when used in high doses or if hypokalemia is present. Use of a beta-1-selective (cardioselective) beta blocker is recommended whenever possible when this combination of drugs must be used together. Monitor the patient's lung and cardiovascular status closely. Beta-agonists and beta-blockers are pharmacologic opposites and will counteract each other to some extent when given concomitantly, especially when non-cardioselective beta blockers are used. (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Midodrine: (Moderate) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Mobocertinib: (Minor) QT/QTc prolongation can occur with concomitant use of mobocertinib and short-acting beta-agonists although the risk of developing torsade de pointes (TdP) is low. Additional steps to minimize the risk of QT/QTc interval prolongation and TdP, such as avoidance, electrolyte monitoring and repletion, and ECG monitoring, may be considered in patients with additional risk factors for TdP. The risk for QT/QTc prolongation may be greater with long-acting beta-agonists than short-acting beta-agonists.
Monoamine oxidase inhibitors: (Moderate) Use beta-agonists with caution in patients receiving concomitant monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping treatment with MAOIs because the action of beta-agonists on the cardiovascular system may be potentiated.
Nadolol: (Moderate) Beta-blockers will block the pulmonary effects of inhaled beta-agonists, and in some cases may exacerbate bronchospasm in patients with reactive airways. Beta-agonists can sometimes increase heart rate or have other cardiovascular effects, particularly when used in high doses or if hypokalemia is present. Use of a beta-1-selective (cardioselective) beta blocker is recommended whenever possible when this combination of drugs must be used together. Monitor the patient's lung and cardiovascular status closely. Beta-agonists and beta-blockers are pharmacologic opposites and will counteract each other to some extent when given concomitantly, especially when non-cardioselective beta blockers are used.
Naproxen; Pseudoephedrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and pseudoephedrine use. Concomitant use may potentiate sympathetic effects.
Nebivolol: (Moderate) Beta-blockers will block the pulmonary effects of inhaled beta-agonists, and in some cases may exacerbate bronchospasm in patients with reactive airways. Beta-agonists can sometimes increase heart rate or have other cardiovascular effects, particularly when used in high doses or if hypokalemia is present. Use of a beta-1-selective (cardioselective) beta blocker is recommended whenever possible when this combination of drugs must be used together. Monitor the patient's lung and cardiovascular status closely. Beta-agonists and beta-blockers are pharmacologic opposites and will counteract each other to some extent when given concomitantly, especially when non-cardioselective beta blockers are used.
Nebivolol; Valsartan: (Moderate) Beta-blockers will block the pulmonary effects of inhaled beta-agonists, and in some cases may exacerbate bronchospasm in patients with reactive airways. Beta-agonists can sometimes increase heart rate or have other cardiovascular effects, particularly when used in high doses or if hypokalemia is present. Use of a beta-1-selective (cardioselective) beta blocker is recommended whenever possible when this combination of drugs must be used together. Monitor the patient's lung and cardiovascular status closely. Beta-agonists and beta-blockers are pharmacologic opposites and will counteract each other to some extent when given concomitantly, especially when non-cardioselective beta blockers are used.
Norepinephrine: (Major) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Olmesartan; Amlodipine; Hydrochlorothiazide, HCTZ: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Olmesartan; Hydrochlorothiazide, HCTZ: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Phendimetrazine: (Moderate) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Phenelzine: (Moderate) Use beta-agonists with caution in patients receiving concomitant monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping treatment with MAOIs because the action of beta-agonists on the cardiovascular system may be potentiated.
Phentermine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and phentermine use. Concomitant use may potentiate sympathetic effects.
Phentermine; Topiramate: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and phentermine use. Concomitant use may potentiate sympathetic effects.
Phenylephrine: (Moderate) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Pindolol: (Moderate) Beta-blockers will block the pulmonary effects of inhaled beta-agonists, and in some cases may exacerbate bronchospasm in patients with reactive airways. Beta-agonists can sometimes increase heart rate or have other cardiovascular effects, particularly when used in high doses or if hypokalemia is present. Use of a beta-1-selective (cardioselective) beta blocker is recommended whenever possible when this combination of drugs must be used together. Monitor the patient's lung and cardiovascular status closely. Beta-agonists and beta-blockers are pharmacologic opposites and will counteract each other to some extent when given concomitantly, especially when non-cardioselective beta blockers are used.
Prilocaine; Epinephrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and epinephrine use. Concomitant use may potentiate sympathetic effects.
Procarbazine: (Major) Procarbazine has MAOI activity and the cardiovascular effects of beta-2 agonists may be potentiated by concomitant use of MAOIs. Although no data are available, procarbazine may interact similarly. Close observation for such effects is prudent, particularly if beta-agonists are administered within two weeks of stopping the MAOI.
Promethazine; Phenylephrine: (Moderate) Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.
Propranolol: (Moderate) Beta-blockers will block the pulmonary effects of inhaled beta-agonists, and in some cases may exacerbate bronchospasm in patients with reactive airways. Beta-agonists can sometimes increase heart rate or have other cardiovascular effects, particularly when used in high doses or if hypokalemia is present. Use of a beta-1-selective (cardioselective) beta blocker is recommended whenever possible when this combination of drugs must be used together. Monitor the patient's lung and cardiovascular status closely. Beta-agonists and beta-blockers are pharmacologic opposites and will counteract each other to some extent when given concomitantly, especially when non-cardioselective beta blockers are used.
Pseudoephedrine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and pseudoephedrine use. Concomitant use may potentiate sympathetic effects.
Pseudoephedrine; Triprolidine: (Moderate) Monitor blood pressure and heart rate during concomitant albuterol and pseudoephedrine use. Concomitant use may potentiate sympathetic effects.
Quinapril; Hydrochlorothiazide, HCTZ: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Racepinephrine: (Major) Racepinephrine is a sympathomimetic drug with agonist actions at both the alpha and beta receptors. Patients using prescription beta-agonists for the treatment of asthma should generally avoid the concurrent use of racepinephrine inhalation since additive cardiovascular and nervous system adverse effects are possible, some which may be undesirable.
Rasagiline: (Moderate) The concomitant use of rasagiline and sympathomimetic agents was not allowed in clinical studies; therefore, caution is advised during concurrent use of rasagiline and respiratory adrenergic agents (e.g., the beta-agonists). Although sympathomimetic agents are contraindicated for use with traditional non-selective monoamine oxidase inhibitors (MAOIs), hypertensive reactions generally are not expected to occur during concurrent use with rasagiline because of the selective monoamine oxidase-B (MAO-B) inhibition of rasagiline at manufacturer recommended doses. However, the cardiovascular effects of beta-2 agonists may be potentiated by concomitant use of MAOIs. At least one case of hypertension occurred in a patient with previous episodes of high blood pressure who was receiving albuterol and selegiline, a selective MAOI related to rasagiline, concurrently. Close observation for such effects is prudent, particularly if beta-2 agonists are administered during or within 2 weeks of use of an MAOI.
Spironolactone; Hydrochlorothiazide, HCTZ: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Telmisartan; Hydrochlorothiazide, HCTZ: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Theophylline, Aminophylline: (Moderate) Beta-agonists are commonly used in conjunction with aminophylline or theophylline therapy. Concomitant use can cause additive CNS stimulation; some patients may experience tremor or nervousness with combined use. More serious effects are rare, but may result in additive cardiovascular effects such as increased blood pressure and heart rate. Methylxanthine derivatives, ((e.g., theophylline and aminophylline) may rarely aggravate the hypokalemic effect seen with beta-agonists. Consider checking potassium levels if clinically indicated. (Moderate) Beta-agonists are commonly used in conjunction with aminophylline or theophylline therapy. Concomitant use can cause additive CNS stimulation; some patients may experience tremor or nervousness with combined use. More serious effects are rare, but may result in additive cardiovascular effects such as increased blood pressure and heart rate. Methylxanthine derivatives, (e.g., theophylline, aminophylline) may rarely aggravate the hypokalemic effect seen with beta-agonists. Consider checking potassium levels if clinically indicated.
Thiazide diuretics: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Thyroid hormones: (Moderate) Monitor blood pressure and heart rate during concomitant beta-agonist and thyroid hormone use. Concurrent use may increase the effects of sympathomimetics or thyroid hormone. Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease.
Timolol: (Moderate) Beta-blockers will block the pulmonary effects of inhaled beta-agonists, and in some cases may exacerbate bronchospasm in patients with reactive airways. Beta-agonists can sometimes increase heart rate or have other cardiovascular effects, particularly when used in high doses or if hypokalemia is present. Use of a beta-1-selective (cardioselective) beta blocker is recommended whenever possible when this combination of drugs must be used together. Monitor the patient's lung and cardiovascular status closely. Beta-agonists and beta-blockers are pharmacologic opposites and will counteract each other to some extent when given concomitantly, especially when non-cardioselective beta blockers are used.
Torsemide: (Moderate) Use beta-agonists and loop diuretics with caution due to risk for ECG changes and/or hypokalemia. The ECG changes and/or hypokalemia that may result from administration of loop diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.
Tranylcypromine: (Moderate) Use beta-agonists with caution in patients receiving concomitant monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping treatment with MAOIs because the action of beta-agonists on the cardiovascular system may be potentiated.
Triamterene; Hydrochlorothiazide, HCTZ: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Valsartan; Hydrochlorothiazide, HCTZ: (Minor) Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is unknown, use caution when coadministering beta-agonists with thiazide diuretics and monitor serum potassium as clinically indicated.
Levalbuterol is the R-isomer of albuterol. It is a moderately selective beta2-adrenergic agonist that stimulates receptors of the smooth muscle in the lungs, uterus, and vasculature supplying skeletal muscle. Results from an in vitro study of binding to human beta-adrenergic receptors demonstrated that levalbuterol has approximately 2-fold greater binding affinity than racemic albuterol and approximately 100-fold greater binding affinity than (S)-albuterol. The R-isomer of albuterol, levalbuterol, is primarily responsible for bronchodilation, while the S-isomer lacks significant bronchodilator effects. Although not confirmed during clinical trials in humans, the S-isomer of albuterol has bronchoconstrictive properties in animal models. Data showing an increase in airway reactivity from the administration of S-albuterol are lacking in humans.
Intracellularly, the actions of levalbuterol are mediated by cyclic AMP, the production of which is augmented by beta2-stimulation. Levalbuterol is believed to work by activating adenylate cyclase, the enzyme responsible for generating cyclic AMP, an intracellular mediator. Increased cyclic AMP leads to activation of protein kinase A, which inhibits phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in relaxation. The net result of beta2-receptor agonism in the lungs is relaxation of bronchial and tracheal smooth muscles, which in turn relieves bronchospasm, reduces airway resistance, facilitates mucous drainage, and increases vital capacity.
Levalbuterol can also inhibit the degranulation and subsequent release of inflammatory autocoids from mast cells. Stimulation of beta2-receptors on peripheral vascular smooth muscle can cause vasodilation and a modest decrease in diastolic blood pressure. Beta2-adrenergic stimulation also results in intracellular accumulation of serum potassium, possibly due to stimulation of the Na/K ATPase pump, leading to moderate degrees of hypokalemia.
Levalbuterol is administered via nebulized or aerosolized oral inhalation. Racemic albuterol crosses the blood-brain barrier and may cross the placenta. R-albuterol appears to be preferentially metabolized in the gastrointestinal tract, presumably by SULT1A3 (sulfotransferase). The primary route of elimination of R-albuterol is through renal excretion (80% to 100%), with 25% to 46% being excreted as unchanged drug in the urine. Less than 20% of the drug is excreted in the feces. The half-life is 3.3 to 4 hours in patients 12 years and older.
Affected cytochrome P450 (CYO450) isoenzymes or drug transporters: None
-Route-Specific Pharmacokinetics
Inhalation Route
Following oral inhalation, levalbuterol is absorbed over several hours from the respiratory tract. Most of an inhaled dose is actually swallowed and absorbed through the GI tract. Plasma levels of levalbuterol after oral inhalation of therapeutic doses are very low. Peak serum concentrations of R-albuterol occur in 0.2 hours.
-Oral inhalation solution: The mean onset time (15% increase in FEV-1) for nebulized doses of 0.63 mg and 1.25 mg levalbuterol was approximately 17 and 10 minutes, respectively. The mean time to peak effect is approximately 1.5 hours. The mean duration (more than a 15% increase in FEV-1) following administration of 0.63 and 1.25 mg doses of levalbuterol is 5 and 6 hours, respectively. In some patients, the duration of effect was as long as 8 hours.
-Oral inhalation aerosol: The mean onset time (15% increase in FEV-1) for aerosolized doses of 90 mcg of levalbuterol (2 inhalations) ranges from 4.5 to 10.2 minutes. The mean time to peak effect is 76 to 78 minutes. The mean duration (more than a 15% increase in FEV-1) following administration of 90 mcg of levalbuterol is 3 hours, with a duration of effect as long as 6 hours in some patients.
-Special Populations
Renal Impairment
Renal insufficiency appears to have no effect on the half-life of racemic albuterol; however, renal clearance of any systemically absorbed drug is decreased by 67%. Caution is advised when administering high doses of levalbuterol to patients with renal insufficiency.